Extending hormonal therapy to 10 years has been found to reduce recurrence in HR-positive breast cancer.
In some cases, genomic blood analysis may be effective enough to replace cancer biopsies.
Biosimilars are likely to rival name-brand treatments for breast and other cancers, and the competition could drive prices down.
Androgen deprivation therapy may be linked to dementia in men with prostate cancer, according to a recent study.
The FDA approved Keytruda to treat metastatic non-small cell lung cancer in the frontline setting.
A recent study showed that caregivers of patients with high-grade gliomas experience a great amount of time burden, even in the earlier stages of diagnosis.
Three treatment options for localized prostate cancer all showed a similar low prostate-specific mortality rate.
Joining cancer registries can help patients and the larger oncology community.